Misplaced Pages

Miriplatin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Miriplatin
Clinical data
Trade namesMiripla
Legal status
Legal status
  • Rx in Japan
Identifiers
IUPAC name
  • Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H68N2O4Pt
Molar mass764.012 g·mol
3D model (JSmol)
SMILES
  • CCCCCCCCCCCCCC(=O).CCCCCCCCCCCCCC(=O).C1CC()(()(C1)N)N.
InChI
  • InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1
  • Key:BGIHRZPJIYJKAZ-BLUNCNMSSA-L

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE). Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.

See also

References

  1. ^ "Miriplatin". Inxight Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
  2. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, et al. (February 2018). "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial". Journal of Gastroenterology. 53 (2): 281–290. doi:10.1007/s00535-017-1374-6. PMC 5846877. PMID 28766016.

External links

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: